Eight Big Pharma firms that stack up on consistently solid earnings

The screen resulted in eight pharmaceutical companies. Here are three to highlight:

Pfizer tied at the top with an EQ score of 100. The company’s large portfolio of patented drugs helps generate strong cash flows year after year. Its size in the industry has helped it build one of the largest economies of scale, key in a business that requires large amounts of funding for drug development.

Pfizer recently received U.S. regulatory emergency use authorization for its COVID-19 oral antiviral treatment, Paxlovid. The treatment, which can be taken at home, has been shown to significantly reduce hospitalizations. Since the announcement on Dec. 22, several analysts have increased their price target for the company’s stock.operates through two business segments: diabetes and obesity care, and biopharmaceuticals. Novo shares the top spot with Pfixer with an EQ score of 100.

Nonetheless, the company is well positioned to defend its market share with its encouraging pipeline of new treatment options.which scored an 88 on the EQ Model, operates through three segments: consumer, pharmaceutical and medical devices. The company is one of the largest pharmas globally, with a market cap of more than US$455-billion. It generates the highest revenue in the industry, with more than US$82-billion reported in 2020, about half of which is pharmaceutical sales.

J&J’s strong free cash flow has allowed the firm to increase its dividend consistently for more than 50 years. In addition, its diversification in several health care segments has prepared it well for any downturns in the economy. However, strong competition and a weak late-stage drug pipeline could hinder long term growth potential.Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lululemon sinks after warning that Omicron could cut earningsLululemon Athletica Inc. said the Omicron variant of COVID\u002D19 has forced it to reduce its earnings expectations for the fourth quarter Let us all take a moment to thank Lululemon for making yoga pants ubiquitous. 🙏
Source: nationalpost - 🏆 10. / 80 Read more »